• Publications
  • Influence
Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer
  • Y. Fan, X. Zhu, +12 authors M. Hu
  • Medicine, Biology
  • Clinical Cancer Research
  • 13 October 2017
Purpose: Leptomeningeal metastasis (LM) is a detrimental complication of non–small cell lung cancer (NSCLC) and associated with poor prognosis. However, the underlying mechanisms of the metastasisExpand
  • 17
  • 1
Advances in antibody therapeutics targeting small-cell lung cancer.
  • H. Lu, Z. Jiang
  • Medicine
  • Advances in clinical and experimental medicine…
  • 16 May 2018
The proportion of small-cell lung cancer (SCLC) among all lung cancers decreased from 17.26% in 1986 to 12.95% in 2002. Chemotherapy is the key mode of treatment. However, novel therapeuticExpand
  • 6
  • 1
Open Access
Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma
BackgroundEsophageal sarcomatoid carcinoma (ESC) is a rare disease with a mixture of both carcinomatous and sarcomatous components in the tumor. Its genetic background and mechanisms of oncogenesisExpand
  • 4
  • 1
Combined small-cell lung carcinoma
  • J. Qin, H. Lu
  • Medicine
  • OncoTargets and therapy
  • 19 June 2018
Currently, studies assessing combined small-cell lung carcinoma (C-SCLC) are relatively scarce and limited. Indeed the clinicopathological features, treatment, and prognosis of patients with C-SCLCExpand
  • 2
  • 1
Open Access
A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung
The aim of the present study was to determine the optimal time for concurrent thoracic radiotherapy (TRT) with etoposide and cisplatin/carboplatin (EP/EC) chemotherapy for the treatment ofExpand
  • 9
Open Access
Advances in antiangiogenic treatment of small-cell lung cancer
Small-cell lung cancer (SCLC), a poorly differentiated neuroendocrine malignancy, has a rapid growth rate, strong aggressiveness, early metastases, and poor prognosis. Angiogenesis greatlyExpand
  • 12
Open Access
The Role and Mechanism of Borneol to Open the Blood-Brain Barrier
Background: The blood-brain barrier (BBB) is the greatest challenge in the treatment of intracranial malignant tumors. Objective: The aim of this study is to determine the role of borneol in openingExpand
  • 7
Adenosquamous carcinoma of the lung
Adenosquamous carcinoma of the lung (ASC), a relatively rare subtype of non-small-cell lung cancer, is defined as a malignancy containing components of lung adenocarcinoma (ADC) and lung squamousExpand
  • 14
Open Access
Effect of metformin in the prognosis of patients with smallcell lung cancer combined with diabetes mellitus.
BACKGROUND The prognosis for small-cell lung cancer (SCLC) is very poor, so a new therapeutic strategy and new drugs are imperative. OBJECTIVES The aim of this study was to examine the effect ofExpand
  • 2
Open Access
Preoperative serum carcinoembryonic antigen levels are associated with histologic subtype, EGFR mutations, and ALK fusion in patients with completely resected lung adenocarcinoma
Background Serum carcinoembryonic antigen (CEA) is often elevated in lung adenocarcinoma, but not in all patients. Meanwhile, epidermal growth factor receptor (EGFR) mutations and anaplastic lymphomaExpand
  • 5
Open Access